What you should know:
1. If completed, the transaction will be Blackstone’s first in the Japanese market.
2. The transaction could close in the second quarter of 2019.
3. Ayumi’s flagship product Calonal is a leading acetaminophen drug used to treat chronic pain.
4. Ayumi also has a comprehensive synthetic and biosimilar product portfolio.
More articles on devices:
AAOS names Dr. Joseph Bosco III 1st vice president — 4 insights
5 insights into new AAHKS President Dr. Michael Bolognesi
HSS surgeon-in-chief emeritus makes $35k donation to high school
